NCT02998671View on ClinicalTrials.gov

Study of Efficacy and Safety of CJM112 in Patients With Moderate to Severe Inflammatory Acne

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

December 22, 2016

Primary Completion Date

August 1, 2018

Study Completion Date

August 1, 2018

Conditions
Acne Vulgaris
Interventions
BIOLOGICAL

CJM112

OTHER

Placebo

Trial Locations (10)

48149

Novartis Investigative Site, Münster

53111

Novartis Investigative Site, Bonn

60590

Novartis Investigative Site, Frankfurt

78759

Novartis Investigative Site, Austin

90230

Novartis Investigative Site, Culver City

91224

Novartis Investigative Site, Pommelsbrunn

95819

Novartis Investigative Site, Sacramento

4624 VT

Novartis Investigative Site, Bergen op Zoom

9713 GZ

Novartis Investigative Site, Groningen

2333 CL

Novartis Investigative Site, Leiden

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY